1. Elewski BE, Hay RJ: Novel treatment strategies for superficial mycoses: Introduction. J Am Acad Dermatol 40:S1–S2, 1999
2. Favre B, Ryder NS: Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by
terbinafine and other antimycotic agents.
Antimicrob Agents Chemother 40:443-447, 1996
3. Katz HI: Drug interactions of the newer oral antifungal agents. Br J Dermatol 141(Suppl. 56):26-32, 1999
4. Ryder NS:
Terbinafine: Mode of action and properties of the squalene epoxidase inhibition.
Br J Dermatol 126(Suppl. 39):2-7, 1992
5. Jensen JC: Clinical pharmacokinetics of
terbinafine (Lamisil).
Clin Exp Dermatol 14:110-113, 1989
6. Balfour JA, Faulds D:
Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.
Drugs 43:259-284, 1992
7. Lamisil Oral Granules [prescribing information]. Stein, Switzerland, Novartis Pharma Stein AG, 2007
8. Elewski BE et al:
Terbinafine hydrochloride oral granules versus oral
griseofulvin suspension in children with tinea capitis: Rof two randomized, investigator-blinded, multicenter, international, controlled trials.
J Am Acad Dermatol 59:41-54, 2008
9. Gupta AK, Skinner AR: Onychomycosis in children: A brief overview with treatment strategies. Pediatr Dermatol 21:74-79, 2004
10. Lamisil. PDR Guide to Drug Interactions, Side Effects, and Indications. Montvale, NJ, Thomson PDR, 2006
11. Sigurgeirsson B et al: L.I.ON. Study: Efficacy and tolerability of continuous
terbinafine (Lamisil) compared to intermittent
itraconazole in the treatment of toenail onychomycosis. Lamisil vs.
Itraconazole in onychomycosis.
Br J Dermatol 141(Suppl. 56):5-14, 2002
12. Sigurgeirsson B et al: Long-term effectiveness of treatment with
terbinafine vs
itraconazole in onychomycosis: A 5-year blinded prospective follow-up study.
Arch Dermatol 138:353-357, 2002
13. De Cuyper C, Hindryckx PH: Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 141(Suppl. 56):15-20, 1999
14. De Backer M, et al: Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of
terbinafine 250 mg/day versus
itraconazole 200 mg/day.
J Am Acad Dermatol 38:S57–S63, 1998
15. Sigurgeirsson B et al: Intermittent versus continuous
terbinafine in the treatment of toenail onychomycosis: A randomized, double-blind comparison.
J Dermatolog Treat 17:38-44, 2006
16. Gupta AK et al: The use of an intermittent
terbinafine regimen for the treatment of dermatophyte toenail onychomycosis.
J Eur Acad Dermatol Venereol 23:256-262, 2009
17. Jennings MB et al: Treatment of toenail onychomycosis with oral
terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial.
J Am Podiatr Med Assoc 96:465-473, 2006
18. Potter LP: The impact of aggressive debridement used as an adjunct therapy with
terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis.
J Dermatolog Treat 18:46-52, 2007
19. Avner S, Nir N, Henri T: Combination of oral
terbinafine and topical
ciclopirox compared to oral
terbinafine for the treatment of onychomycosis.
J Dermatolog Treat 16:327-330, 2005
20. Baran R et al: A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral
terbinafine compared with oral
terbinafine alone for the treatment of onychomycosis with matrix involvement.
Br J Dermatol 157:149-157, 2007
21. Villars V, Jones
TC: Clinical efficacy and tolerability of
terbinafine (Lamisil)—A new topical and systemic fungicidal drug for treatment of dermatomycoses.
Clin Exp Dermatol 14:124-127, 1989
22. Lamisil [prescribing information]. Stein, Switzerland, Novartis Pharma Stein AG, 2001
23. Scaparro E et al: Evaluation of the efficacy and tolerability of oral
terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial.
Br J Dermatol 144:854-857, 2001
24. Vena GA et al: Oral
terbinafine in the treatment of multi-site seborrhoic dermatitis: A multicenter, double-blind placebo-controlled study.
Int J Immunopathol Pharmacol 18:745-753, 2005
25. Budimulja U, Paul C: One-week
terbinafine 1% solution in pityriasis versicolor: Twice-daily application is more effective than once-daily.
J Dermatolog Treat 13:39-40, 2002
26. Gupta AK, Konnikov N, Lynde CW: Single-blind, randomized, prospective study on
terbinafine and
itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
J Am Acad Dermatol 44:479-484, 2001
27. Tavakkol A, Fellman S, Kianifard F: Safety and efficacy of oral
terbinafine in the treatment of onychomycosis: Analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.
Am J Geriatr Pharmacother 4:1-13, 2006
28. Kovacs MJ et al: Neutropenia and pancytopenia associated with oral
terbinafine.
J Am Acad Dermatol 31:806, 1994
29. Roberts DT: Oral
terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails.
Dermatology 194(Suppl. 1):37-39, 1997
30. Wilson NJ, Evans S: Severe pustular psoriasis provoked by oral
terbinafine.
Br J Dermatol 139:168, 1998
31. Bong JL, Lucke TW, Evans CD: Persistent impairment of taste resulting from
terbinafine.
Br J Dermatol 139:747-748, 1998
32. Brooke R, Coulson IH, al-Dawoud A: Terbinafine-induced subacute cutaneous lupus erythematosus. Br J Dermatol 139:1132-1133, 1998
33. Dupin N et al: Acute generalized exanthematous pustulosis induced by
terbinafine.
Arch Dermatol 132:1253-1254, 1996
34. Gupta AK: Hepatitis associated with
terbinafine therapy: Three case reports and a review of the literature.
Clin Exp Dermatol 23:64-67, 1998
35. Lowe G, Green C, Jennings P: Hepatitis associated with
terbinafine treatment.
BMJ 306:248, 1993
36. Ornstein DL, Ely P: Reversible agranulocytosis associated with oral
terbinafine for onychomycosis.
J Am Acad Dermatol 39:1023-1024, 1998
37. Carstens J, et al: Toxic epidermal necrolysis and erythema multiforme following therapy with
terbinafine.
Acta Derm Venereol 74:391-392, 1994
38. Brodell RT, Elewski BE: Clinical pearl: Systemic antifungal drugs and drug interactions. J Am Acad Dermatol 33:259-260, 1995
39. Smith EB: The treatment of dermatophytosis: Safety considerations. J Am Acad Dermatol 43:S113–S119, 2000
40. Abdel-Rahman SM, et al: Investigation of
terbinafine as a CYP2D6 inhibitor in vivo.
Clin Pharmacol Ther 65:465-472, 1999
41. Hall M et al: Safety of oral
terbinafine: Results of a postmarketing surveillance study in 25,884 patients.
Arch Dermatol 133:1213-1219, 1997
43. Schmutz JL, Barbaud A, Trechot P: [Overdose of
nortriptyline during treatment with
terbinafine (1st reported case)].
Ann Dermatol Venereol 126:647, 1999
44. Heykants J et al: The clinical pharmacokinetics of
itraconazole: An overview.
Mycoses 32(Suppl. 1):67-87, 1989
45. Friedlander SF: The optimal therapy for tinea capitis. Pediatr Dermatol 17:325-326, 2000
46. Haria M, Bryson HM, Goa KL:
Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.
Drugs 51:585-620, 1996
47. Van Cutsem J: The in-vitro antifungal spectrum of
itraconazole.
Mycoses 32(Suppl. 1):7-13, 1989
48. Vanden Bossche H et al: Biochemical basis for the activity and selectivity of oral antifungal drugs. Br J Clin Pract Suppl 71:41-46, 1990
49. Barone JA et al: Food interaction and steady-state pharmacokinetics of
itraconazole capsules in healthy male volunteers.
Antimicrob Agents Chemother 37:778-784, 1993
50. Zimmermann T et al: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents,
itraconazole and
fluconazole.
Eur J Clin Pharmacol 46:147-150, 1994
51. Negroni R, Arechavala AI:
Itraconazole: Pharmacokinetics and indications.
Arch Med Res 24:387-393, 1993
52. Van de Velde VJ et al: Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of
itraconazole.
Pharmacotherapy 16:424-428, 1996
53. Steinbach WJ: Antifungal agents in children. Pediatr Clin North Am 52:895-915, viii, 2005
54. Sporanox. PDR Guide to Drug Interactions, Side Effects, and Indications. Montvale, NJ, Thomson PDR, 2006
55. Gupta AK, Cooper EA, Ginter G: Efficacy and safety of
itraconazole use in children.
Dermatol Clin 21:521-535, 2003
56. Elewski BE: Treatment of tinea capitis: Beyond
griseofulvin.
J Am Acad Dermatol 40:S27-30, 1999
57. Elewski BE: New developments in cutaneous fungal infections. Curr Probl Dermatol 12:81-85, 2000
58. Gupta AK et al: Therapeutic options for the treatment of tinea capitis caused by Trichophyton species:
Griseofulvin versus the new oral antifungal agents,
terbinafine,
itraconazole, and
fluconazole.
Pediatr Dermatol 18:433-438, 2001
59. Gupta AK et al: Tinea capitis: An overview with emphasis on management. Pediatr Dermatol 16:171-189, 1999
60. Havu V et al: A double-blind, randomized study comparing
itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis.
Br J Dermatol 136:230-234, 1997
61. Gupta AK et al:
Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks.
J Am Acad Dermatol 36:789-792, 1997
62. Gupta AK et al: Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol 21:417-425, 2003
63. Gupta AK et al: Hepatic safety of
itraconazole.
J Cutan Med Surg 6:210-213, 2002
64. Tucker RM et al: Adverse events associated with
itraconazole in 189 patients on chronic therapy.
J Antimicrob Chemother 26:561-566, 1990
65. Rosen T: Debilitating edema associated with
itraconazole therapy.
Arch Dermatol 130:260-261, 1994
66. Sporanox [prescribing information]. Titusville, NJ, Janssen Pharmaceutica, 2004
67. Viagra [prescribing information]. New York, Pfizer, 2000
68. Friedlander SF: Tinea capitis—Past, present and future. Curr Probl Dermatol 30:278-281, 2000
69. Montero-Gei F:
Fluconazole: Pharmacokinetics and indications.
Arch Med Res 24:377-385, 1993
70. Thorpe JE, Baker N, Bromet-Petit M: Effect of oral antacid administration on the pharmacokinetics of oral
fluconazole.
Antimicrob Agents Chemother 34:2032-2033, 1990
71. Dudley MN: Clinical pharmacology of
fluconazole.
Pharmacotherapy 10:141S–145S, 1990
72. Tucker RM et al: Treatment of coccidioidal meningitis with
fluconazole.
Rev Infect Dis 12(Suppl. 3):S380-9, 1990
73. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of
fluconazole in humans.
Rev Infect Dis 12(Suppl. 3):S318-S326, 1990
74. Ruhnke M et al: Single-dose pharmacokinetics of
fluconazole in patients with liver cirrhosis.
J Antimicrob Chemother 35:641-647, 1995
75. Toon S et al: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of
fluconazole.
Br J Clin Pharmacol 29:221-226, 1990
76. Solomon BA et al:
Fluconazole for the treatment of tinea capitis in children.
J Am Acad Dermatol 37:274-275, 1997
77. Foster KW et al: A randomized controlled trial assessing the efficacy of
fluconazole in the treatment of pediatric tinea capitis.
J Am Acad Dermatol 53:798-809, 2005
78. Sobel JD et al. Maintenance
fluconazole therapy for recurrent vulvovaginal candidiasis.
N Engl J Med 351:876-883, 2004
79. Martinez RC et al: Improved treatment of vulvovaginal candidiasis with
fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
Lett Appl Microbiol 48:269-274, 2009
80. Hamza OJ et al: Single-dose
fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, double-blind, double-dummy trial.
Clin Infect Dis 47:1270-1276, 2008
81. Del Aguila R et al: Once-weekly oral doses of
fluconazole 150 mg in the treatment of tinea pedis.
Clin Exp Dermatol 17:402-406, 1992
82. Havu V et al. A double-blind, randomized study to compare the efficacy and safety of
terbinafine (Lamisil) with
fluconazole (Diflucan) in the treatment of onychomycosis.
Br J Dermatol 142:97-102, 2000
83. Faergemann J: Treatment of pityriasis versicolor with a single dose of
fluconazole.
Acta Derm Venereol 72:74-75, 1992
84. Partap R et al: Single-dose
fluconazole versus
itraconazole in pityriasis versicolor.
Dermatology 208:55-59, 2004
85. Comert A et al: Efficacy of oral
fluconazole in the treatment of seborrheic dermatitis: A placebo-controlled study.
Am J Clin Dermatol 8:235-238, 2007
86. Martin MV: The use of
fluconazole and
itraconazole in the treatment of Candida albicans infections: A review.
J Antimicrob Chemother 44:429-437, 1999
87. Diflucan. PDR Guide to Drug Interactions, Side Effects, and Indications. Montvale, NJ, Thomson PDR, 2006
88. Oral
fluconazole for vaginal candidiasis.
Med Lett Drugs Ther 36:81-82, 1994
89. Pappas PG et al: Alopecia associated with
fluconazole therapy.
Ann Intern Med 123:354-357, 1995
90. Somchit N et al: Hepatotoxicity induced by antifungal drugs
itraconazole and
fluconazole in rats: A comparative in vivo study.
Hum Exp Toxicol 23:519-525, 2004
91. Tholakanahalli VN et al: Fluconazole-induced torsade de pointes. Ann Pharmacother 35:432-434, 2001
92. Pasqualotto
AC et al:
Voriconazole therapeutic drug monitoring: Focus on safety.
Expert Opin Drug Saf 9:125-137, 2010
93. Chen SC, Sorrell
TC: Antifungal agents.
Med J Aust 187:404-409, 2007
94. Malani AN, Aronoff DM: Voriconazole-induced photosensitivity. Clin Med Res 6:83-85, 2008
95. Auffret N et al: [
Voriconazole photosensitivity: 7 cases].
Ann Dermatol Venereol 133:330-332, 2006
96. Racette AJ et al: Photoaging and phototoxicity from long-term
voriconazole treatment in a 15-year-old girl.
J Am Acad Dermatol 52:S81–85, 2005
97. Dolan CK et al: Pseudoporphyria as a result of
voriconazole use: A case report.
Int J Dermatol 43:768-771, 2004
98. Tolland JP, McKeown PP, Corbett JR: Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed 23:29-31, 2007
99. Huang DB, Wu JJ, Lahart CJ: Toxic epidermal necrolysis as a complication of treatment with
voriconazole.
South Med J 97:1116-1117, 2004
100. Curigliano G et al. Life-threatening toxic epidermal necrolysis during
voriconazole therapy for invasive aspergillosis after chemotherapy.
Ann Oncol 17:1174-1175, 2006
101. Miller DD et al: Maleoma associated with Long-term
voriconazole therapy: A new manisfestation of chronic photosensitivity.
Arch Dermatol 146:300-304, 2010
102. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview. Part I. J Am Acad Dermatol 30:677-98; quiz 698-700, 1994
103. Meinhof W: Kinetics and spectrum of activity of oral antifungals: The therapeutic implications. J Am Acad Dermatol 29:S37–41, 1993
104. Castellsague J et al: Risk of serious skin disorders among users of oral antifungals: A population-based study. BMC Dermatol 2:14, 2002
105. Faergemann J et al: A multicentre (double-blind) comparative study to assess the safety and efficacy of
fluconazole and
griseofulvin in the treatment of tinea corporis and tinea cruris.
Br J Dermatol 136:575-577, 1997
106. Grifulvin V. PDR Guide to Drug Interactions, Side Effects, and Indications. Montvale, NJ, Thomson PDR, 2006
107. Gris-PEG. PDR Guide to Drug Interactions, Side Effects, and Indications. Montvale, NJ, Thomson PDR, 2006
108. Vassileva SG, Mateev G, Parish LC: Antimicrobial photosensitive reactions. Arch Intern Med 158:1993-2000, 1998
109. Callaghan CJ, Bradley JA: Current status of renal transplantation. Methods Mol Biol 333:1-28, 2006
110. Cecka JM: The OPTN/UNOS Renal Transplant Registry 2003. Clin Transpl 1–12, 2003
111. Perera GK et al: Skin lesions in adult liver transplant recipients: A study of 100 consecutive patients. Br J Dermatol 154:868-872, 2006
112. Richardson MD: Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56(Suppl. 1):i5–i11, 2005
113. Phillips P et al: A double-blind comparison of
itraconazole oral solution and
fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS.
Clin Infect Dis 26:1368-1373, 1998
114. Potter M: Strategies for managing systemic fungal infection and the place of
itraconazole.
J Antimicrob Chemother 56(Suppl. 1):i49–i54, 2005
115. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating
posaconazole versus
fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Clin Infect Dis 42:1179-1186, 2006
116. Turner MS, Drew RH, Perfect JR: Emerging echinocandins for treatment of invasive fungal infections. Expert Opin Emerg Drugs 11:231-250, 2006
117. Rand S: Overview: The treatment of dermatophytosis. J Am Acad Dermatol 43:S104–112, 2000